Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) EPS (Basic): 2022-2025

Historic EPS (Basic) for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$0.41.

  • Centessa Pharmaceuticals' EPS (Basic) fell 10.81% to -$0.41 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.90, marking a year-over-year decrease of 25.00%. This contributed to the annual value of -$2.06 for FY2024, which is 31.21% down from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' EPS (Basic) stood at -$0.41, which was down 7.89% from -$0.38 recorded in Q2 2025.
  • Centessa Pharmaceuticals' EPS (Basic)'s 5-year high stood at -$0.20 during Q1 2025, with a 5-year trough of -$0.91 in Q4 2024.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.38 (2025), whereas its average is -$0.42.
  • Per our database at Business Quant, Centessa Pharmaceuticals' EPS (Basic) skyrocketed by 62.32% in 2023 and then slumped by 145.95% in 2024.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' EPS (Basic) stood at -$0.45 in 2022, then climbed by 17.78% to -$0.37 in 2023, then crashed by 145.95% to -$0.91 in 2024, then decreased by 10.81% to -$0.41 in 2025.
  • Its EPS (Basic) stands at -$0.41 for Q3 2025, versus -$0.38 for Q2 2025 and -$0.20 for Q1 2025.